InvestingDaily.com

Account Information

  • My Account

    Manage all your subscriptions, update your address, email preferences and change your password.

  • Help Center

    Get answers to common service questions, ask the analyst or contact our customer service department.

  • My Stock Talk Profile

    Update your stock talk name and/or picture.



Close
FEATURED STRATEGY

These contrarian stocks thrive in good markets and bad

These contrarian stocks thrive in good markets and badIn my new profit guide, I reveal a group of super-safe stocks that don’t behave like regular stocks during market downturns. In fact, these rock-solid beauties historically SKYROCKET and THRIVE during the worst of times. During the last three market busts, stocks in this contrarian sector soared 42%… 135%… and even 200%. Do yourself a favor. Check out my free profit guide today.

 

Buying Best IPO Performers of Last Year Can Backfire

By Linda McDonough on October 14, 2015

Investors are always on the hunt for the next undiscovered stock.  What better place to look than the IPO market?  Here is the land of newborns, baby stocks newly christened into the world of capitalism and ready to burst with potential growth.

We thought the same, but after analyzing the performance of 2014’s best performing IPOs, we think not. We warn investors that toddler tantrums, schoolyard scuffles and adolescent rebellion often precede the calm and predictable nature of a mature stock.

The top ten performing IPOs of 2014 gained an average of 223% from their IPO price until year end. Every single one of them at least doubled with the top gainer, Radius Healthcare (Nasdaq: RDUS), skyrocketing an astounding 387%.  One would imagine these companies’ business models and prospects were well vetted by investors.

Yet in 2015, these ten stocks have returned an average loss of 14%.  When digging further into the numbers the carnage is ugly.  Of the 2014 top ten IPOs, only four are up in 2015.  Of the six decliners, their average loss was 56%!

It can be tempting to jump on board Global Blood Therapeutics (Nasdaq: GBT), the best performing IPO of 2015.  The company, whose novel manner intent on discovering therapies for blood disorders, certainly sounds exciting.

But are you smart enough to tell the difference between a Global Blood Therapeutics and Avalanche Biotechnologies (Nasdaq: AAVL) whose stock gained 218% in 2014 only to see it crater 84% this year due to an abandoned clinical trial?  

We recognize that biotech investing introduces a whole new level of risk but gut wrenching drops have not been reserved solely for biotechs. Truecar Inc. (Nasdaq: TRUE), who sells sales leads to auto dealerships, has collapsed 74% this year after losing its biggest contract with AutoNation (NYSE: AN). GoPro (Nasdaq: GPRO), the infamous purveyor of thrill-capturing cameras, has dropped 52%.

It’s not that we don’t like IPOs.  Depending on the market’s fancy, IPOs can provide solid prospects to investors.  Unfortunately, the last two years’ best-loved new issues have been focused on biotech or fast growing companies with little profits.  It’s always wise to keep your eyes open for new names but the warning of “past performance is no indication of future profits” is more relevant than ever.


You might also enjoy…

 

Forget Buy and Hold. Here’s how to retire faster…

I’m not a fan of “buy and hold.” Gurus like to tell you that patience is the key, but I call horse puckey.

We’ve discovered an investing technique that consistently pays out easy-to-repeat profits.

One that’s proven to beat the market 2,082% in head-to-head testing.

And one that’s generated over 488 winners since 2011.

This method is so powerful, in fact, some of the investors we’ve let use it reported back to us saying they’ve made $71,425… $82,371… and even as much as $151,000 in a single year thanks to this “trick.”

That’s how powerful this investing technique is!

What what exactly is this mysterious method? I’ve put all the details together here.

Stock Talk — Post a comment Comment Guidelines

Our Stock Talk section is reserved for productive dialogue pertaining to the content and portfolio recommendations of this service. We reserve the right to remove any comments we feel do not benefit other readers. If you have a general investment comment not related to this article, please post to our Stock Talk page. If you have a personal question about your subscription or need technical help, please contact our customer service team. And if you have any success stories to share with our analysts, they’re always happy to hear them. Note that we may use your kind words in our promotional materials. Thank you.

You must be logged in to post to Stock Talk OR create an account.

Create a new Investing Daily account

  • - OR -

* Investing Daily will use any information you provide in a manner consistent with our Privacy Policy. Your email address is used for account verification and will remain private.